Plus Therapeutics (PSTV) Amortization of Deferred Charges (2016 - 2024)
Plus Therapeutics has reported Amortization of Deferred Charges over the past 15 years, most recently at $4000.0 for Q2 2024.
- Quarterly Amortization of Deferred Charges fell 92.45% to $4000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Dec 2024, down 89.47% year-over-year, with the annual reading at $20000.0 for FY2024, 89.47% down from the prior year.
- Amortization of Deferred Charges was $4000.0 for Q2 2024 at Plus Therapeutics, down from $16000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $156000.0 in Q4 2020 and troughed at $4000.0 in Q2 2024.
- The 5-year median for Amortization of Deferred Charges is $91000.0 (2022), against an average of $88933.3.
- Year-over-year, Amortization of Deferred Charges skyrocketed 71.91% in 2020 and then plummeted 92.45% in 2024.
- A 5-year view of Amortization of Deferred Charges shows it stood at $156000.0 in 2020, then dropped by 3.21% to $151000.0 in 2021, then crashed by 47.02% to $80000.0 in 2022, then plummeted by 62.5% to $30000.0 in 2023, then tumbled by 86.67% to $4000.0 in 2024.
- Per Business Quant, the three most recent readings for PSTV's Amortization of Deferred Charges are $4000.0 (Q2 2024), $16000.0 (Q1 2024), and $30000.0 (Q4 2023).